Fourteen deals, and not one new owner

Fourteen deals reached us between Monday and Friday: ten from the commercial register, four from the press. We read the ten registry filings in full. Every one was a completion, a parent absorbing a subsidiary whose shares it already owned outright, or a branch struck from the register after its head office merged. Not one recorded a new change of control. Nor did the other four: a joint venture over property, an IP carve-out, and two minority stakes in companies that are not Swiss.

That distinction matters if you count register events as deal flow, because the notices say so plainly. In the French filings the phrase is that the absorbing company holds all the shares of the transferring one, so no capital increase and no share allocation follow. What you are reading is paperwork catching up with decisions already taken. The merger contracts behind this week's filings are dated 29 May, 8 June and 19 June.

The week's real money went elsewhere. Vaderis Therapeutics in Basel closed an oversubscribed USD 152.5 million Series B on 11 August, led by Life Sciences at Goldman Sachs Alternatives and TCGX, and began a global Phase 3 trial. That is more than any disclosed Swiss M&A price this week. Netcloud AG took a CHF 75.4 million network-equipment award on 13 August, larger than most mid-market deals we track, and the kind of number that never reaches a deal database at all.

The largest transaction touching a Swiss balance sheet was not a sale either. Varia US Properties handed Brookfield ninety per cent of a USD 694 million joint venture covering thirteen of its seventeen American properties, and kept ten per cent plus a role running them. For a listed vehicle whose shares trade below the value of what it owns, that is the exit that does not crystallise the discount.